Vertex Pharmaceuticals Incorpor

VRTX

$434.02

Name : Vertex Pharmaceuticals Incorpor

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $111,278,669,824.00

EPSttm : 14.21

Vertex Pharmaceuticals Incorpor

$434.02

0.72%

$3.13

Float Short %

1.63

Margin Of Safety %

Put/Call OI Ratio

0.62

EPS Next Q Diff

0.17

EPS Last/This Y

20.53

EPS This/Next Y

1.6

Price

434.01

Target Price

488.85

Analyst Recom

1.86

Performance Q

11.07

Relative Volume

0.86

Beta

0.32

Ticker: VRTX

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	VRTX	419.1	0.58	0.96	39921
2025-10-21	VRTX	426.28	0.59	0.81	40784
2025-10-22	VRTX	428.25	0.59	0.73	41565
2025-10-23	VRTX	422.69	0.60	2.43	41940
2025-10-24	VRTX	421.31	0.60	3.56	42442
2025-10-27	VRTX	420.04	0.62	1.41	40622
2025-10-28	VRTX	422.53	0.64	3.88	40925
2025-10-29	VRTX	417.19	0.66	2.54	41810
2025-10-30	VRTX	419.98	0.66	1.98	42100
2025-10-31	VRTX	425.56	0.67	1.52	42444
2025-11-03	VRTX	428.31	0.66	1.03	41055
2025-11-04	VRTX	421.67	0.70	0.82	46341
2025-11-05	VRTX	417.12	0.67	1.81	47929
2025-11-06	VRTX	416.57	0.67	0.58	48970
2025-11-07	VRTX	409.42	0.66	1.26	49740
2025-11-10	VRTX	421.25	0.65	0.99	43239
2025-11-11	VRTX	429.29	0.64	1.12	43839
2025-11-12	VRTX	434.47	0.64	0.83	44089
2025-11-13	VRTX	434.76	0.64	1.20	45061
2025-11-14	VRTX	437.33	0.65	1.53	45681
2025-11-17	VRTX	434.1	0.62	0.66	42668
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	VRTX	419.10	4.8	1840.7	17.96
2025-10-21	VRTX	426.39	4.8	1917.9	17.96
2025-10-22	VRTX	426.44	5.0	1807.6	17.95
2025-10-23	VRTX	422.43	5.0	1744.0	17.95
2025-10-24	VRTX	421.45	5.0	1786.9	17.95
2025-10-27	VRTX	420.05	5.0	1784.4	17.95
2025-10-28	VRTX	422.39	4.9	1839.3	17.94
2025-10-29	VRTX	417.14	4.9	1724.3	17.94
2025-10-30	VRTX	419.89	4.7	1846.7	18.01
2025-10-31	VRTX	425.57	4.7	1892.8	18.01
2025-11-03	VRTX	426.10	4.7	1813.1	18.01
2025-11-04	VRTX	421.47	4.7	1712.5	18.01
2025-11-05	VRTX	417.06	4.7	1710.5	18.01
2025-11-06	VRTX	416.28	36.9	1662.4	18.88
2025-11-07	VRTX	409.47	28.7	1569.2	18.47
2025-11-10	VRTX	421.20	29.3	1857.1	18.47
2025-11-11	VRTX	429.22	29.2	1527.9	18.39
2025-11-12	VRTX	434.38	29.2	1484.8	18.39
2025-11-13	VRTX	434.72	29.2	1418.7	18.39
2025-11-14	VRTX	437.13	29.2	1448.0	18.39
2025-11-17	VRTX	434.01	29.8	1367.3	18.45
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	VRTX	1.80	0.43	1.39
2025-10-21	VRTX	1.80	0.43	1.39
2025-10-22	VRTX	1.80	0.43	1.39
2025-10-23	VRTX	1.80	0.43	1.39
2025-10-24	VRTX	1.80	0.43	1.39
2025-10-27	VRTX	1.80	0.35	1.39
2025-10-28	VRTX	1.80	0.35	1.39
2025-10-29	VRTX	1.80	0.35	1.39
2025-10-30	VRTX	1.80	0.35	1.39
2025-10-31	VRTX	1.80	0.35	1.39
2025-11-03	VRTX	1.80	0.52	1.39
2025-11-04	VRTX	1.80	0.52	1.39
2025-11-05	VRTX	1.80	0.52	1.39
2025-11-06	VRTX	1.85	0.52	1.39
2025-11-07	VRTX	1.87	0.52	1.41
2025-11-10	VRTX	1.87	-1.02	1.41
2025-11-11	VRTX	1.87	-1.02	1.41
2025-11-12	VRTX	1.87	-1.02	1.63
2025-11-13	VRTX	1.87	-1.02	1.63
2025-11-14	VRTX	1.87	-1.02	1.63
2025-11-17	VRTX	-7.23	-1.12	1.63
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

4.8

Avg. EPS Est. Current Quarter

5.16

Avg. EPS Est. Next Quarter

4.97

Insider Transactions

-7.23

Institutional Transactions

-1.12

Beta

0.32

Average Sales Estimate Current Quarter

3199

Average Sales Estimate Next Quarter

3141

Fair Value

498.78

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

16.5

Max Drawdown 5-Year %

-29.1

Target Price

488.85

P/E

30.59

Forward P/E

21.4

PEG

P/S

9.38

P/B

6.36

P/Free Cash Flow

EPS

14.19

Average EPS Est. Cur. Y

18.45

EPS Next Y. (Est.)

20.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

31.32

Relative Volume

0.86

Return on Equity vs Sector %

-5.7

Return on Equity vs Industry %

9.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.51

EBIT Estimation

1367.3

Vertex Pharmaceuticals Incorpor

Sector: Healthcare

Industry: Biotechnology

Employees: 6100

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; and Entrada Therapeutics, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

stock quote shares VRTX – Vertex Pharmaceuticals Incorporated Stock Price stock today

news today VRTX – Vertex Pharmaceuticals Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch VRTX – Vertex Pharmaceuticals Incorporated yahoo finance google finance

stock history VRTX – Vertex Pharmaceuticals Incorporated invest stock market

stock prices VRTX premarket after hours

ticker VRTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VRTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y